Regular intake of benzodiazepines, widely used to treat insomnia and anxiety, may be associated with an increased risk of Alzheimer's disease, a study has warned.
Even though the increased risk for Alzheimer's disease was small in this study, the threshold for prescribing benzodiazepines and related drugs should be high enough due to their several adverse effects and events, such as falls, said researchers from the University of Eastern Finland.
These medications are commonly used for sleep problems, but their effectiveness for this indication diminishes over weeks or months. However, the risk of adverse events remains in longer-term use.
The results, published in Acta Psychiatrica Scandinavica, showed that the risk increase was similar with both benzodiazepines and Z drugs regardless of their half-life.
The study included all Finnish community dwellers with newly diagnosed Alzheimer's disease in 70,719 persons, and their age, sex and region of residence matched controls (282,862 persons).
Many chronic disorders, substance abuse, socioeconomical position and use of antidepressants and antipsychotics were taken into account. To account for reverse causality, drug use within 5 years before Alzheimer's disease diagnosis was not taken into account.
After adjustment for other psychotropics, it is possible that the association may partially be due to antidepressants and/or antipsychotics, or concomitant use of these medications, the researchers noted.
--IANS
rt/anp/sed
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
